The tetracyclic compounds 3-6 as well as their frameworks 1 and 2 have been submitted to a preliminary screening by the National Cancer Institute (NCI) for evaluation in an in vitro preclinical antitumor screening program [11] [12] [13] against 60 human tumor cell lines derived from leukemia, non-small cell lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer. The dose-response curves for each cell line were measured in all compounds with five different drug concentrations (10 Ϫ4 -10 Ϫ8 M) and the concen- -2-phenyl (1) and 1,3-dimethyl-2-phenyl (2) -substituted pyrrole[2,3-d ]pyridazinones, as well as their tetracyclic analogues 3-6, were synthesized and evaluated in vitro by the National Cancer Institute against 60 human tumor cell lines derived from nine cancer cell types. Biological results showed that the antitumor activities of these compounds were related to the planarity of their ring systems with potency increasing in the order 2Ͻ4Ӎ5Ͻ6Ͻ3. Among them, the most potent compound 3 showed significant cell line cytotoxicity, particularly against the renal cancer subpanel [GI 50 (m mM) 5.07] and displayed significant potency [GI 50 (m mM) 3.04-4.32] against MOLT-4, SR (leukemia), NCI-H460 (non-small cell lung), HCT-116 (colon), and SF-295 (CNS) cancer cells, respectively.
The pyrrole [2,3-d] pyridazine (I) system is rarely reported on the literature. Although the synthesis of I derivatives was first described by Fisher more than 70 years ago, [1] [2] [3] to our knowledge only two reports have appeared since then dealing with pyrrole [2,3-d] pyridazin-4-ones (II) as inhibitors of human cancer cell proliferation 4) and with pyrrole [2,3-d ]pyridazin-7-ones (III) as carbohydrate-modified nucleosides active as antiviral and antiproliferative agents. 5) Our continuing interest in the chemistry and pharmacology of pyridazines and polycyclic congeners 6) led us to incorporate II into tetracyclic derivatives 3-6 provided with an almost planar structure potentially intercalating 7) with DNA, and to test them as inhibitors of human cancer cell proliferation. In addition, 1-methyl-2-phenylpyrrole [2,3-d] pyridazin-4-one (1) and substituted 1,3-dimethyl-2-phenylpyrrole [2,3d] pyridazin-4-one (2) derived from 3 by removal or cleavage of the carbon bridge between the phenyl and pyrrole moieties were synthesized to compare the variation in biological effects due to the loss of planarity of the ring system.
A survey of the literature revealed that not only the tetracyclic compounds 3-6 but also the pyrrolepyridazinones 1 and 2 were unknown.
Chemistry
The synthesis of 1 and 2 as well as of 3-6 was performed following a common strategy. That is, formylation of the appropriate esters 7a-f with Vilsmeier's reagent in acetonitrile afforded the corresponding 2-formyl derivatives 8a-f which were finally condensed with hydrazine to give the desired compounds 1-6 (Chart 3).
The starting esters 7 were obtained by the following procedures. The synthesis of 7a, c, d was performed by condensing the appropriate bromoketone 9a, c, d with ethyl cyanoacetate to give the cyanoketoesters 10, which after reaction with gaseous HCl in Et 2 O cyclized to the pyrrole derivatives 11. N-Methylation of 11 with Me 2 SO 4 and KOH in EtOH, followed by dehalogenation of 12 with HCOONH 4 and 10% Pd-C, gave 7a, c, d (Chart 4). The 3-methyl derivative 7b was in turn obtained by N-deacetylation of the known ethyl 1-acetyl-2-phenyl-3-methylpyrrole-4-carboxylate 13, 8) followed by N-methylation with Me 2 SO 4 and KOH in EtOH (Chart 5).
The synthesis of the benzocycloheptapyrrole ester 7e was carried out by a sigmatropic rearrangement 9, 10) of the adduct (16) of benzosuberone oxime 15 with methyl propiolate to give 17, which was finally N-methylated as reported above to 7e (Chart 6). Finally, the benzo[g]indole derivative 7f was obtained by dehydrogenation of 7d with DDQ in CH 2 Cl 2 (Chart 7). tration causing 50% cell growth inhibition (GI 50 ) as compared to the control was calculated ( Table 1 ). Among the tetracyclic structures 3-6, a significant activity was found for the indenopyrrole [2,3-d] pyridazinone 3 (XϭCH 2 ) (GI 50 ϭ 11.7 mM) and for the benzo[g]pyridazin [4,5-b] indol-7-one 6 (XϭCHϭCH) (GI 50 ϭ15.5 mM). In particular, compound 3 exhibited significant cell line-selective cytotoxicity against the renal cancer subpanel (GI 50 ϭ3.46 mM) and against MOLT-4, SR (leukemia), NCI-H460 (non-small cell lung), HCT-116 (colon) and SF-295 (CNS) cancer cells, respectively ( Fig. 1) . Interestingly, the inhibition properties in this series seem to be related to the planarity of the ring system, with compounds 4 (XϭCH 2 CH 2 ) and 5 (XϭCH 2 CH 2 CH 2 ) being less active (GI 50 of 26.9 and 24.5 mM, respectively).
However, this hypothesis is not consistent with the results for 1-methyl-2-phenylpyrrole[2,3-d]pyridazinone 1, which was inactive, and 1,3-dimethyl-2-phenylpyrrole [2,3-d] pyridazinone 2, which possessed only weak activity (GI 50 ϭ36.3 mM), thus revealing that planarity does not greatly influence anticellular activity.
In conclusion, the synthesis and preliminary evaluation of the tetracyclic structures 3-6 derived from indenopyridazi-none suggest that the observed cytotoxic activity could derived from intercalation of the planar structures with DNA. On the basis of this hypothesis compounds 3 and 6 will be selected as lead compounds for a structure-activity study involving the replacement of the amidic 4-carbonyl with aminic side chains to increase interaction with nucleic acids. Further research on this is in progress.
Experimental
Chemistry, General Unless otherwise noted, all materials were obtained from commercial suppliers and used without purification. Flash chromatography was performed using Merck Silica Gel 60 (230-400 mesh ASTM). Thin-layer chromatography (TLC) was performed with Polygram ® SIL N-HR-/HV 254 precoated plastic sheets (0.2 mm). 1 H-NMR spectra were measured in CDCl 3 with superconducting FT-NMR using a XL-200 Varian apparatus at 200 MHz.
Chemical shifts are expressed in d (ppm) downfield from internal tetramethylsilane (TMS) and coupling constants in Hz. Significant 1 H-NMR data are reported in the following order: multiplicity (s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet), number of protons, and coupling constants in Hz. IR spectra were recorded as thin films or Nujol mulls on NaCl plates with a Perkin-Elmer 781 IR spectrophotometer and are expressed in n (cm Ϫ1 ). UV-VIS spectra were recorded as ethanolic solutions with Perkin-Elmer Lambda 5 and Hitachi U-2001 spectrophotometers and the absorption wavelengths are expressed in nm followed by (log e). Melting points were determined on a Thomas Hoover capillary melting point apparatus and are uncorrected.
Starting benzosuberone oxime and a-bromotetral-1-ones were prepared as described in the literature, 14, 15) a-bromoacetophenone, a-bromoindan-1one were commercially available (Aldrich Chemical Co.).
The physico-chemical data of the compounds 1-17 are reported in Tables 2 and 3.
General Alkylation Procedure for Compounds 10a, c, d A solution of the bromo-derivative (5 mmol) in acetone (11 ml) was added dropwise to a suspension of NCCH 2 CO 2 Et (40 mmol) and K 2 CO 3 (10 mmol) at 40-45°C. The reaction mixture was stirred at 40-45°C for 1 h and then cooled at room temperature. After the addition of AcOEt (10 ml) and water (10 ml) under stirring, the organic layer was separated, washed with a solution of 10% KH 2 PO 4 (7.5 ml) and brine (5 ml), dried (Na 2 SO 4 ), concentrated under reduced pressure to give a crude oil. The oil was distilled (150°C/1 mmHg) to remove excess NCCH 2 CO 2 Et and the residue was purified by flash chromatography (Petroleum ether/AcOEt, 8/2) to give the desired products 10a, c, d.
Ethyl 2 ) RϭH (1), CH 3 (2) Xϭ-CH 2 (3), -(CH 2 ) 2 (4), -(CH 2 ) 3 (5) , -CHϭCH (6) Cell line 15 H 15 NO 3 : C, 70.02; H, 5.87; N, 5.44; Found: C, 70.20; H, 5.89; N, 5.47 .
General Procedure for Compounds 11a, c, d A solution of the cyanoketo esters (10a, c, d) (6.7 mmol) in Et 2 O (30 ml for 10a, d, 15 ml for 10c), cooled at a 0-5°C in an ice-water bath, was bubbled with gaseous HCl (1.86 g, 5.1 mmol). The solution was stirred at room temperature for 24 h. Then excess HCl and Et 2 O were removed by flashing with N 2 . The solid residue was triturated in MeOH to give 11a, c, d as cream-colored crystals.
Ethyl 2 7.11 (t, 1H, CH), 7.25 (t, 1H, CH), 7.42 (d, 1H, CH), 7.47 (d, 1H, CH), 11.58 (br s, 1H, NH exchanged with D 2 O) . Anal. Calcd for C 14 H 12 ClNO 2 : C, 64.25; H, 4.62; Cl, 13.54; N, 5.35; Found: C, 64.08; H, 4.60; Cl, 13.40; N, indole-3-carboxylate (11d): IR: 1660 (CϭO), 3210 (NH); UV: 222.5 (4.55), 233.5 (4.36), 291.5 (4.45), 296.0 (4.47), 309.0 (4. ClNO 2 : C, 65.34; H, 5.11; Cl, 12.85; N, 5.07; Found: C, 65.51; H, 5.14; Cl, 12.90; N, 5.09 .
General Procedure for Compounds 12a, c, d and 7b, e KOH 0.28 g (4.99 mmol) was dissolved in a solution of chloroesters 11a, c, d or esters 14 and 17 (4.14 mmol) in EtOH (23 ml). The solvent was then removed under reduced pressure and to the residue dissolved in acetone (18.6 ml) and Me 2 SO 4 0.78 ml (8.28 mmol) was added. The mixture was stirred at room temperature (30 min for 11c, 1 h for 11a and 14, 3 h for 17, 4.5 h for 11d) .
The solid precipitate was filtered off and the solution concentrated under reduced pressure to give an oil that solidified on standing.
Ethyl 1 , 5.35; Cl, 13.44; N, 5.31; Found: C, 63.56; H, 5.31; Cl, 13.41; N, 5. , 5.11; Cl, 12.87; N, 5.08; Found: C, 65.52; H, 5.12; Cl, 12.91; N, 5.10 .
Ethyl 1-Methyl-2-chloro-4,5-dihydro-1H-benzo[g]indole-3-carboxylate (12d): IR: 1700 (CϭO); UV: 223.5 (4.48), 234.0 (4.35), 296.5 (4.38), 308.0 The numerical values listed are GI 50 values, which are the molar concentrations causing 50% growth inhibition.
